Chemistry:Sofinicline
Sofinicline (INN, USAN; developmental code names ABT-894 and A-422894.0) is a nicotinic acetylcholine receptor (nAChR) agonist which was under development for the treatment of attention deficit hyperactivity disorder (ADHD), cognition disorders, and diabetic neuropathies but was never marketed.[1][2][3] It is taken orally.[1][3]
The drug acts as a highly selective full agonist of the α4β2 nicotinic acetylcholine receptor.[3] It has been found to enhance cognition and memory in rodents.[3] Sofinicline's affinity for the receptor is approximately 0.1 nM.[3] The time to peak levels of sofinicline is 2 to 4 hours and its elimination half-life is 4 to 6 hours.[3] Other pharmacokinetic data for sofinicline have also been reported.[3] Side effects of sofinicline in humans include increased heart rate, nausea, dizziness, headache, and fatigue.[3]
Sofinicline was under development by Abbott Laboratories and NeuroSearch.[1][2] It reached phase 2 clinical trials for ADHD and neuropathic pain and the preclinical research stage of development for cognition disorders prior to the discontinuation of its development.[1][2]
See also
- List of investigational attention deficit hyperactivity disorder drugs
- List of investigational analgesics
References
- ↑ 1.0 1.1 1.2 1.3 "Sofinicline". 23 January 2013. https://adisinsight.springer.com/drugs/800019709.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Sofinicline with Synapse". 16 May 2026. https://synapse.patsnap.com/drug/dd00d583ceca438d960c4c74d28b467d.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 "Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder". Expert Opinion on Investigational Drugs 23 (8): 1157–1163. August 2014. doi:10.1517/13543784.2014.934806. PMID 24965900.
 |  |
